DcR3 combined with hematological traits serves as a valuable biomarker for the diagnosis of cancer metastasis.

Decoy receptor 3 (DcR3) is abnormally up-regulated in many cancer cells. It may help cancer cells to escape from immune surveillance and establish metastatic lesions. However, whether DcR3 can be used as a biomarker for the diagnosis of cancer metastasis is unclear. In this study, sera from healthy controls and patients with different cancers were collected, and tested for their DcR3 levels by ELISA. Significantly elevated DcR3 levels were observed in the sera of patients with gastric cancer (2.04 ± 1.01, = 0.0061), lymphoma (1.62 ± 0.75, = 0.041), and breast cancer (1.53 ± 0.51, = 0.023). DcR3 was found to be a suitable biomarker for identifying gastric cancer patients. Importantly, DcR3 was positively associated with platelet distribution width (PDW) ( = 2.45 × 10, = 0.63) in metastatic cancers but negatively associated with hemoglobin (HGB) ( = 0.002, = -0.59) and hematocrit (HCT) ( = 0.001, = -0.62) in non-metastatic cancers. Combined with PDW, HGB and HCT, serum DcR3 could be used to predict the occurrence of cancer metastasis. These findings indicate that DcR3 could be used as a biomarker for the diagnosis of gastric cancer, and for cancer metastasis in combination with hematological traits.